Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.
| Condition(s) | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy. |
| Who can participate | Inclusion Criteria: 1. A subject has completed or discontinued from an Intellia-sponsored clinical study in which a complete or partial dose of NTLA-2001 was received. 2. A subject has provided informed consent for the LTFU study. Exclusion Criteria: None |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Intellia Therapeutics |
| Locations | Paris, France; Auckland, New Zealand; Umeå, Sweden; London, United Kingdom |
| Start date | 2023-07-10 |
| NCT ID | NCT05697861 |
| Official listing | https://clinicaltrials.gov/study/NCT05697861 |